ibuprofen has been researched along with Lung Diseases in 25 studies
Midol: combination of cinnamedrine, phenacetin, aspirin & caffeine
Lung Diseases: Pathological processes involving any part of the LUNG.
| Excerpt | Relevance | Reference |
|---|---|---|
| "In patients with cystic fibrosis and mild lung disease, high-dose ibuprofen, taken consistently for four years, significantly slows the progression of the lung disease without serious adverse effects." | 9.08 | Effect of high-dose ibuprofen in patients with cystic fibrosis. ( Byard, PJ; Davis, PB; Hoppel, CL; Konstan, MW, 1995) |
| "This report demonstrates that gastrointestinal tract anatomical abnormalities or dysmotility may be contraindications for therapy with high-dose ibuprofen in patients with cystic fibrosis." | 8.82 | High-dose ibuprofen therapy associated with esophageal ulceration after pneumonectomy in a patient with cystic fibrosis: a case report. ( Anbar, RD; Mackey, JE, 2004) |
| "Despite its apparent benefits, high-dose ibuprofen has been infrequently applied to children with cystic fibrosis." | 7.74 | Use of high-dose ibuprofen in a pediatric cystic fibrosis center. ( Boyle, M; Fennell, PB; Ferkol, T; Quante, J; Strunk, R; Wilson, K, 2007) |
| " We have previously shown that ibuprofen, a nonsteroidal anti-inflammatory drug, can improve the hemodynamic alterations of canine endotoxin shock." | 7.67 | Effects of ibuprofen on neutrophil function and acute lung injury in canine endotoxin shock. ( Balk, RA; Bone, RC; Jacobs, RF; Townsend, JW; Tryka, AF; Walls, RC, 1988) |
| "Ibuprofen did not increase the pulmonary burden of Pseudomonas, and the ibuprofen-treated infected animals gained weight better than placebo-treated controls." | 5.28 | Ibuprofen attenuates the inflammatory response to Pseudomonas aeruginosa in a rat model of chronic pulmonary infection. Implications for antiinflammatory therapy in cystic fibrosis. ( Davis, PB; Konstan, MW; Vargo, KM, 1990) |
| "In patients with cystic fibrosis and mild lung disease, high-dose ibuprofen, taken consistently for four years, significantly slows the progression of the lung disease without serious adverse effects." | 5.08 | Effect of high-dose ibuprofen in patients with cystic fibrosis. ( Byard, PJ; Davis, PB; Hoppel, CL; Konstan, MW, 1995) |
| "This report demonstrates that gastrointestinal tract anatomical abnormalities or dysmotility may be contraindications for therapy with high-dose ibuprofen in patients with cystic fibrosis." | 4.82 | High-dose ibuprofen therapy associated with esophageal ulceration after pneumonectomy in a patient with cystic fibrosis: a case report. ( Anbar, RD; Mackey, JE, 2004) |
| "Despite its apparent benefits, high-dose ibuprofen has been infrequently applied to children with cystic fibrosis." | 3.74 | Use of high-dose ibuprofen in a pediatric cystic fibrosis center. ( Boyle, M; Fennell, PB; Ferkol, T; Quante, J; Strunk, R; Wilson, K, 2007) |
| "Hypochlorous acid (HOCl), a neutrophil-generated oxidant, has been implicated in tissue destruction in sepsis-induced acute lung injury (ALI)." | 3.68 | Ibuprofen attenuates hypochlorous acid production from neutrophils in porcine acute lung injury. ( Byrne, K; Carey, PD; Fowler, AA; Jenkins, JK; Sielaff, TD; Sugerman, HJ; Walsh, CJ, 1990) |
| " We have previously shown that ibuprofen, a nonsteroidal anti-inflammatory drug, can improve the hemodynamic alterations of canine endotoxin shock." | 3.67 | Effects of ibuprofen on neutrophil function and acute lung injury in canine endotoxin shock. ( Balk, RA; Bone, RC; Jacobs, RF; Townsend, JW; Tryka, AF; Walls, RC, 1988) |
| "We studied lung clearance of aerosolized technetium-labeled diethylenetriamine pentaacetic acid (99mTcDTPA), plasma concentrations of 6-keto-PGF1 alpha and thromboxane B2, and pulmonary edema as indices of lung injury in rabbits exposed to cigarette smoke (CSE)." | 3.67 | Acute cigarette smoke exposure causes lung injury in rabbits treated with ibuprofen. ( Bruck, DC; Lemen, RJ; Magarelli, JL; Quan, SF; Sobonya, RE; Witten, ML, 1987) |
| "We injected Escherichia coli endotoxin, 2 micrograms/kg, beneath the eschar of sheep with 25% total body surface full-thickness burns to determine whether burn tissue in the presence of endotoxin releases prostanoids, particularly thromboxane A2, (TxA2), and if increased local TxA2 production can lead to distant lung dysfunction." | 3.67 | Endotoxin-induced prostanoid production by the burn wound can cause distant lung dysfunction. ( Demling, RH; Hechtman, H; Lalonde, CC; Wenger, H; West, K; Wong, C, 1986) |
| "Ibuprofen pretreatment prevented the sepsis associated increase in both Kf and lung lavage protein concentration." | 1.29 | Cecal ligation and puncture is associated with pulmonary injury in the rat: role of cyclooxygenase pathway products. ( Carlson, RW; Schneidkraut, MJ, 1993) |
| "Ibuprofen pretreatment attenuates the enhanced neutrophil (PMN) respiratory burst and reduces increased plasma tumor necrosis factor (TNF) activity in porcine sepsis-induced acute lung injury (ALI)." | 1.28 | Delayed cyclo-oxygenase blockade reduces the neutrophil respiratory burst and plasma tumor necrosis factor levels in sepsis-induced acute lung injury. ( Byrne, K; Carey, PD; Fowler, AA; Leeper-Woodford, SK; Sugerman, HJ; Walsh, CJ, 1991) |
| "Ibuprofen did not increase the pulmonary burden of Pseudomonas, and the ibuprofen-treated infected animals gained weight better than placebo-treated controls." | 1.28 | Ibuprofen attenuates the inflammatory response to Pseudomonas aeruginosa in a rat model of chronic pulmonary infection. Implications for antiinflammatory therapy in cystic fibrosis. ( Davis, PB; Konstan, MW; Vargo, KM, 1990) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 11 (44.00) | 18.7374 |
| 1990's | 8 (32.00) | 18.2507 |
| 2000's | 3 (12.00) | 29.6817 |
| 2010's | 2 (8.00) | 24.3611 |
| 2020's | 1 (4.00) | 2.80 |
| Authors | Studies |
|---|---|
| Mitra, S | 1 |
| Scrivens, A | 1 |
| von Kursell, AM | 1 |
| Disher, T | 1 |
| Erdeve, O | 1 |
| Yurttutan, S | 1 |
| Altug, N | 1 |
| Ozdemir, R | 1 |
| Gokmen, T | 1 |
| Dilmen, U | 1 |
| Oguz, SS | 1 |
| Uras, N | 1 |
| Adrouche-Amrani, L | 1 |
| Green, RS | 1 |
| Gluck, KM | 1 |
| Lin, J | 1 |
| Mackey, JE | 1 |
| Anbar, RD | 1 |
| Fennell, PB | 1 |
| Quante, J | 1 |
| Wilson, K | 1 |
| Boyle, M | 1 |
| Strunk, R | 1 |
| Ferkol, T | 1 |
| Miyahara, T | 1 |
| Hamanaka, K | 1 |
| Weber, DS | 1 |
| Anghelescu, M | 1 |
| Frost, JR | 1 |
| King, JA | 1 |
| Parker, JC | 1 |
| Perkowski, SZ | 1 |
| Havill, AM | 1 |
| Flynn, JT | 1 |
| Gee, MH | 1 |
| Konstan, MW | 2 |
| Byard, PJ | 1 |
| Hoppel, CL | 1 |
| Davis, PB | 2 |
| Schneidkraut, MJ | 1 |
| Carlson, RW | 1 |
| Wheeler, AP | 1 |
| Hardie, WD | 1 |
| Bernard, GR | 1 |
| Carey, PD | 3 |
| Leeper-Woodford, SK | 2 |
| Walsh, CJ | 2 |
| Byrne, K | 3 |
| Fowler, AA | 3 |
| Sugerman, HJ | 3 |
| Fisher, BJ | 1 |
| Blocher, C | 1 |
| Zanaboni, PB | 1 |
| Bradley, JD | 1 |
| Webster, RO | 1 |
| Dahms, TE | 2 |
| Vargo, KM | 1 |
| Jenkins, JK | 1 |
| Sielaff, TD | 1 |
| White, CW | 1 |
| Ghezzi, P | 1 |
| Norris, AA | 1 |
| Jackson, DM | 1 |
| Fuhrman, TM | 1 |
| Hollon, MF | 1 |
| Reines, HD | 1 |
| Olanoff, LS | 1 |
| Halushka, PV | 1 |
| Balk, RA | 1 |
| Jacobs, RF | 1 |
| Tryka, AF | 1 |
| Townsend, JW | 1 |
| Walls, RC | 1 |
| Bone, RC | 1 |
| Witten, ML | 1 |
| Lemen, RJ | 1 |
| Quan, SF | 1 |
| Sobonya, RE | 1 |
| Magarelli, JL | 1 |
| Bruck, DC | 1 |
| Kimura, R | 1 |
| Traber, L | 1 |
| Herndon, D | 1 |
| Niehaus, G | 1 |
| Flynn, J | 1 |
| Traber, DL | 1 |
| Sprague, RS | 1 |
| Stephenson, AH | 1 |
| Asner, NG | 1 |
| Lonigro, AJ | 1 |
| Wenger, H | 2 |
| Wong, C | 2 |
| Demling, RH | 2 |
| Voelkel, NF | 1 |
| Lalonde, CC | 1 |
| Hechtman, H | 1 |
| West, K | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Impact of Early Targeted Ibuprofene Treatment of Patent Ductus Arteriosus (PDA) on Long Term Neurodevelopmental Outcome in Very Premature Infants (TRIOCAPI)[NCT01630278] | Phase 3 | 363 participants (Actual) | Interventional | 2012-03-31 | Completed | ||
| Combination of Acetaminophen and Ibuprofen in the Management of Patent Ductus Arteriosus in Premature Infants: A Pilot Study[NCT03103022] | Phase 1 | 20 participants (Actual) | Interventional | 2017-06-12 | Completed | ||
| Liberal Versus Restrictive Platelet Transfusion for Treatment of Hemodynamically Significant Patent Ductus Arteriosus in Thrombocytopenic Preterm Neonates- A Randomized Open Label, Controlled Trial[NCT03022253] | Phase 3 | 44 participants (Anticipated) | Interventional | 2016-03-31 | Completed | ||
| Evaluation of the Effect of Sulforaphane in Broccoli Sprouts on Nrf2 Activation, Measures of Oxidative Stress, and Neutrophil Migration to Mucosal Surfaces in Healthy and CF Subjects[NCT01315665] | 15 participants (Actual) | Interventional | 2011-04-30 | Completed | |||
| The Role of IL-17 Neutrophils in CF Lung Inflammation[NCT02025829] | 14 participants (Actual) | Observational | 2014-02-28 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Change in gingival neutrophils measured after 5 days of study treatment (consuming broccoli sprouts). Patients will perform mouthwashes with normal saline. Neutrophil counts will be performed on fresh samples. Acridine orange will be added to the saline rinses and neutrophils will be counted under the microscope. (NCT01315665)
Timeframe: Baseline and end of 5 day treatment period
| Intervention | Neutrophils/mL (Log10) (Mean) |
|---|---|
| Healthy Volunteers | -0.06 |
| Subjects With Cystic Fibrosis | -0.02 |
Change in lymphocyte glutathione measurements after 5 days of study treatment (consuming broccoli sprouts). (NCT01315665)
Timeframe: Baseline and end of 5 day treatment period
| Intervention | Micro Molar (Mean) |
|---|---|
| Healthy Volunteers | 14.3 |
| Subjects With Cystic Fibrosis | 4.7 |
Change in urine bromotyrosine (measured by mass spectrometry) will be measured after 5 days of study treatment (consuming broccoli sprouts). (NCT01315665)
Timeframe: Baseline and end of 5 day treatment period
| Intervention | ng/mg creatinine (Log10) (Mean) |
|---|---|
| Healthy Volunteers | 0.09 |
| Subjects With Cystic Fibrosis | 0.01 |
Number of subjects with activated Nrf-2 in the cytoplasm of nasal epithelial cells after 5 days of study treatment (consuming broccoli sprouts) (NCT01315665)
Timeframe: Baseline and of end of 5 day treatment period
| Intervention | participants (Number) | |
|---|---|---|
| Baseline | Day 5, End of treatment | |
| Healthy Volunteers | 0 | 4 |
| Subjects With Cystic Fibrosis | 0 | 4 |
In the Exacerbation/IV Antibiotics Cohort--Subjects will serve as their own controls. The percentage of neutrophils (in sputum) positive for IL-17 was determined by flow cytometry for each subject at the beginning and end of treatment for a pulmonary exacerbation. Sputum IL-17 neutrophil counts will be compared to the change in lung function (FEV1) as determined by spirometry (American Thoracic Society standards). (NCT02025829)
Timeframe: End of Treatment, two weeks. Samples will be obtained from each study volunteer at the beginning of IV antibiotic treatment and at the completion of antibiotic treatment for a pulmonary exacerbation
| Intervention | % of neutrophils positive for IL-17 (Mean) |
|---|---|
| Begining of Exacerbation | 55 |
| End of Exacerbation | 4 |
In the Exacerbation/IV Antibiotics Cohort--Measurement of sputum inflammatory mediators by multiplex assay for IL-1β, IL-6, IL-8, and IL-17A. Neutrophil elastase determined by colorimetric assay. Measurements at the beginning of IV antibiotic treatment and after 2 weeks antibiotic treatment for a pulmonary exacerbation (NCT02025829)
Timeframe: End of Treatment, two weeks. Samples will be obtained from each study volunteer at the beginning of IV antibiotic treatment and at the completion of antibiotic treatment for a pulmonary exacerbation
| Intervention | pg/ml (Mean) | ||||
|---|---|---|---|---|---|
| IL-1b (pg/ml) | IL-6 (pg/ml) | IL-8 (pg/ml) | IL-17 (pg/ml) | Neutrophil elastase activity (pg/ml) | |
| Begining of Exacerbation | 2313 | 53 | 5785 | 302 | 195 |
| End of Exacerbation | 757 | 37 | 3428 | 147 | 53 |
3 reviews available for ibuprofen and Lung Diseases
| Article | Year |
|---|---|
Early treatment versus expectant management of hemodynamically significant patent ductus arteriosus for preterm infants.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Cause of Death; Cerebral Intraventricular Hemorrhage; Chron | 2020 |
High-dose ibuprofen therapy associated with esophageal ulceration after pneumonectomy in a patient with cystic fibrosis: a case report.
Topics: Adolescent; Anti-Inflammatory Agents, Non-Steroidal; Barrett Esophagus; Combined Modality Therapy; C | 2004 |
Species variations in the pulmonary responses to arachidonic acid metabolites.
Topics: Airway Resistance; Animals; Animals, Newborn; Arachidonic Acids; Bronchi; Child; Fetus; Humans; Ibup | 1985 |
2 trials available for ibuprofen and Lung Diseases
| Article | Year |
|---|---|
Oral versus intravenous ibuprofen for patent ductus arteriosus closure: a randomised controlled trial in extremely low birthweight infants.
Topics: Administration, Oral; Birth Weight; Chronic Disease; Cyclooxygenase Inhibitors; Ductus Arteriosus, P | 2012 |
Effect of high-dose ibuprofen in patients with cystic fibrosis.
Topics: Adolescent; Adult; Child; Child, Preschool; Cystic Fibrosis; Double-Blind Method; Female; Forced Exp | 1995 |
Effect of high-dose ibuprofen in patients with cystic fibrosis.
Topics: Adolescent; Adult; Child; Child, Preschool; Cystic Fibrosis; Double-Blind Method; Female; Forced Exp | 1995 |
Effect of high-dose ibuprofen in patients with cystic fibrosis.
Topics: Adolescent; Adult; Child; Child, Preschool; Cystic Fibrosis; Double-Blind Method; Female; Forced Exp | 1995 |
Effect of high-dose ibuprofen in patients with cystic fibrosis.
Topics: Adolescent; Adult; Child; Child, Preschool; Cystic Fibrosis; Double-Blind Method; Female; Forced Exp | 1995 |
20 other studies available for ibuprofen and Lung Diseases
| Article | Year |
|---|---|
Failure of a repeat course of cyclooxygenase inhibitor to close a PDA is a risk factor for developing chronic lung disease in ELBW infants.
Topics: Chronic Disease; Cyclooxygenase Inhibitors; Drug Administration Schedule; Ductus Arteriosus, Patent; | 2012 |
Use of high-dose ibuprofen in a pediatric cystic fibrosis center.
Topics: Adolescent; Anti-Inflammatory Agents, Non-Steroidal; Child; Child, Preschool; Cystic Fibrosis; Femal | 2007 |
Cytosolic phospholipase A2 and arachidonic acid metabolites modulate ventilator-induced permeability increases in isolated mouse lungs.
Topics: Animals; Arachidonic Acid; Arachidonic Acids; Bronchoalveolar Lavage Fluid; Capillary Permeability; | 2008 |
Role of intrapulmonary release of eicosanoids and superoxide anion as mediators of pulmonary dysfunction and endothelial injury in sheep with intermittent complement activation.
Topics: Animals; Capillary Permeability; Chemotaxis, Leukocyte; Complement Activation; Endothelium; Hyperten | 1983 |
Cecal ligation and puncture is associated with pulmonary injury in the rat: role of cyclooxygenase pathway products.
Topics: Animals; Bronchoalveolar Lavage Fluid; Capillaries; Capillary Permeability; Cecum; Ibuprofen; Ligati | 1993 |
The role of cyclooxygenase products in lung injury induced by tumor necrosis factor in sheep.
Topics: Animals; Drug Evaluation, Preclinical; Eicosanoids; Hemodynamics; Ibuprofen; Lung Diseases; Lymph; P | 1992 |
Delayed cyclo-oxygenase blockade reduces the neutrophil respiratory burst and plasma tumor necrosis factor levels in sepsis-induced acute lung injury.
Topics: Animals; Bronchoalveolar Lavage Fluid; Capillary Permeability; Cyclooxygenase Inhibitors; Extravascu | 1991 |
Ibuprofen attenuates plasma tumor necrosis factor activity during sepsis-induced acute lung injury.
Topics: Acute Disease; Animals; Blood Gas Analysis; Blood Pressure; Cardiac Output; Extravascular Lung Water | 1991 |
Cyclooxygenase inhibitors prevent ethchlorvynol-induced injury in rat and rabbit lungs.
Topics: Animals; Capillary Permeability; Cyclooxygenase Inhibitors; Ethchlorvynol; Ibuprofen; In Vitro Techn | 1991 |
Ibuprofen attenuates the inflammatory response to Pseudomonas aeruginosa in a rat model of chronic pulmonary infection. Implications for antiinflammatory therapy in cystic fibrosis.
Topics: Animals; Body Weight; Chronic Disease; Cystic Fibrosis; Dinoprostone; Humans; Ibuprofen; Leukotriene | 1990 |
Ibuprofen attenuates hypochlorous acid production from neutrophils in porcine acute lung injury.
Topics: Animals; Bronchoalveolar Lavage Fluid; Capillary Permeability; Cyclooxygenase Inhibitors; Extravascu | 1990 |
Protection against pulmonary oxygen toxicity by interleukin-1 and tumor necrosis factor: role of antioxidant enzymes and effect of cyclooxygenase inhibitors.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Antioxidants; Aspirin; Cyclooxygenase Inhibitors; | 1989 |
Sulphur dioxide-induced airway hyperreactivity and pulmonary inflammation in dogs.
Topics: Animals; Dogs; Female; Histamine; Ibuprofen; Inflammation; Lung; Lung Diseases; Macrophages; Male; N | 1989 |
Beneficial effects of ibuprofen in oleic acid induced lung injury.
Topics: Animals; Arachidonic Acid; Arachidonic Acids; Dogs; Extracellular Space; Hemodynamics; Ibuprofen; Lu | 1987 |
Effects of ibuprofen on neutrophil function and acute lung injury in canine endotoxin shock.
Topics: Acute Disease; Animals; Bronchoalveolar Lavage Fluid; Cell Adhesion; Dogs; Dose-Response Relationshi | 1988 |
Acute cigarette smoke exposure causes lung injury in rabbits treated with ibuprofen.
Topics: 6-Ketoprostaglandin F1 alpha; Animals; Female; Ibuprofen; Lung; Lung Diseases; Male; Nicotiana; Orga | 1987 |
Ibuprofen reduces the lung lymph flow changes associated with inhalation injury.
Topics: Animals; Burns, Inhalation; Extracellular Space; Ibuprofen; Lung; Lung Diseases; Lymph; Sheep | 1988 |
Effects of ibuprofen on the hypoxemia of established ethchlorvynol-induced unilateral acute lung injury in anesthetized dogs.
Topics: Animals; Dogs; Ethchlorvynol; Hemodynamics; Hypoxia; Ibuprofen; Lung Diseases; Male | 1987 |
Pulmonary dysfunction secondary to soft-tissue endotoxin.
Topics: 6-Ketoprostaglandin F1 alpha; Animals; Endotoxins; Escherichia coli; Hypertension, Pulmonary; Hypoxi | 1985 |
Endotoxin-induced prostanoid production by the burn wound can cause distant lung dysfunction.
Topics: Animals; Burns; Endotoxins; Hemodynamics; Ibuprofen; Injections, Intravenous; Lung Diseases; Lymph; | 1986 |